title: Depot and oral antipsychotics: patient preferences and attitudes are not the same thing.
abstract: Some clinicians believe that antipsychotic depot injections are unacceptable to patients. This cross-sectional study investigated patients' attitudes regarding antipsychotics, and included within-participant comparisons. Two hundred and twenty-two out-patients with schizophrenia/schizoaffective disorder completed the Drug Attitude Inventory (DAI-10), scales on insight, side effects and treatment preferences. Formulation preference was associated with current medication formulation: depots were preferred by 43% (33/76) on depot vs 6% (8/146) on orals (P < 0.001). Attitudes (DAI scores) regarding current formulation were influenced by illness duration, extrapyramidal symptoms and insight but not by formulation (depot vs oral). For those with experience of both formulations, participants currently on tablets scored depots less favourably than oral (4.27 vs 6.89, P < 0.001); those on depot did not differentiate. When voluntary patients on maintenance antipsychotics are asked about their attitudes to their current medication, those on depot respond similarly to those on oral. However, when asked to state a preference for formulation (depot vs oral), patients tend to favour their current formulation. Whatever leads some to switch from depot to oral, leaves a lasting negative impression of the depot and this may limit uptake of newer depots.
authors.affiliation: Institute of Psychiatry, Division of Psychological Medicine, London, UK. m.patel@iop.kcl.ac.uk
authors.forename: M X
authors.initials: MX
authors.lastname: Patel
authors.forename: N
authors.initials: N
authors.lastname: De Zoysa
authors.forename: M
authors.initials: M
authors.lastname: Bernadt
authors.forename: A
authors.initials: A
authors.lastname: David
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001290:Attitude; D002626:Chemistry, Pharmaceutical; D003430:Cross-Sectional Studies; D003692:Delayed-Action Preparations / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D011618:Psychotic Disorders / Q000188:drug therapy / Q000523:psychology*; D012559:Schizophrenia / Q000188:drug therapy; D012565:Schizophrenic Psychology; D011795:Surveys and Questionnaires
chemical_list: D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations